hepat
b
infecti
diseas
caus
hepat
b
virus
hbv
affect
liver
caus
acut
chronic
infect
mani
peopl
symptom
dure
initi
infect
develop
rapid
onset
sick
vomit
yellowish
skin
tired
dark
urin
abdomin
pain
symptom
week
rare
doe
initi
infect
result
death
30
180
day
symptom
begin
infect
time
birth
90
develop
chronic
hepat
b
10
infect
age
five
chronic
diseas
symptom
howev
cirrhosi
liver
cancer
eventu
develop
complic
result
death
15
25
chronic
diseas
virus
transmit
exposur
infecti
blood
bodi
fluid
infect
time
birth
contact
peopl
blood
dure
childhood
frequent
method
hepat
b
acquir
area
diseas
common
area
diseas
rare
intraven
drug
use
sexual
intercours
frequent
rout
infect
risk
factor
includ
work
healthcar
blood
transfus
dialysi
live
infect
person
travel
countri
infect
rate
high
live
institut
tattoo
acupunctur
led
signific
number
case
1980s
howev
becom
common
improv
steril
hepat
b
virus
spread
hold
hand
share
eat
utensil
kiss
hug
cough
sneez
breastfeed
infect
diagnos
30
60
day
exposur
diagnosi
usual
confirm
test
blood
virus
antibodi
virus
one
five
main
hepat
virus
b
c
d
e
infect
prevent
vaccin
sinc
1982
vaccin
recommend
world
health
organ
day
life
possibl
two
three
dose
requir
later
time
effect
vaccin
work
95
time
180
countri
gave
vaccin
nation
program
2006
recommend
blood
test
hepat
b
befor
transfus
condom
use
prevent
infect
dure
initi
infect
care
base
symptom
person
develop
chronic
diseas
antivir
medic
tenofovir
interferon
use
howev
drug
expens
liver
transplant
sometim
use
cirrhosi
world
popul
infect
one
point
live
includ
343
million
chronic
infect
anoth
129
million
new
infect
occur
2013
750,000
peopl
die
hepat
b
year
300,000
liver
cancer
diseas
onli
common
east
asia
sub-saharan
africa
5
10
adult
chronic
infect
rate
europ
north
america
1
origin
known
serum
hepat
research
look
creat
food
contain
hbv
vaccin
diseas
affect
great
ape
sign
symptom
acut
infect
hepat
b
virus
associ
acut
viral
hepat
ill
begin
general
ill-health
loss
appetit
nausea
vomit
bodi
ach
mild
fever
dark
urin
progress
develop
jaundic
note
itchi
skin
indic
possibl
symptom
hepat
virus
type
ill
week
gradual
improv
affect
peopl
peopl
sever
form
liver
diseas
known
fulmin
hepat
failur
die
result
infect
entir
asymptomat
unrecogn
chronic
infect
hepat
b
virus
asymptomat
associ
chronic
inflamm
liver
chronic
hepat
lead
cirrhosi
period
sever
year
type
infect
dramat
increas
incid
hepatocellular
carcinoma
hcc
liver
cancer
europ
hepat
b
c
caus
approxim
50
hepatocellular
carcinoma
chronic
carrier
encourag
avoid
consum
alcohol
increas
risk
cirrhosi
liver
cancer
hepat
b
virus
link
develop
membran
glomerulonephr
mgn
symptom
outsid
liver
present
1
10
hbv-infect
peopl
includ
serum-sick
like
syndrom
acut
necrot
vascul
polyarter
nodosa
membran
glomerulonephr
papular
acrodermat
childhood
gianotti
crosti
syndrom
serum-sick
like
syndrom
occur
set
acut
hepat
b
preced
onset
jaundic
clinic
featur
fever
skin
rash
polyarter
symptom
subsid
short
onset
jaundic
persist
durat
acut
hepat
b
30
50
peopl
acut
necrot
vascul
polyarter
nodosa
hbv
carrier
hbv-associ
nephropathi
describ
adult
common
children
membran
glomerulonephr
common
form
immune-medi
hematolog
disord
essenti
mix
cryoglobulinemia
aplast
anemia
describ
extrahepat
manifest
hbv
infect
associ
well-defin
therefor
probabl
consid
etiolog
link
hbv
caus
transmiss
transmiss
hepat
b
virus
result
exposur
infecti
blood
bodi
fluid
contain
blood
50
100
time
infecti
human
immunodefici
virus
hiv
possibl
form
transmiss
includ
sexual
contact
blood
transfus
transfus
human
blood
product
re-us
contamin
needl
syring
vertic
transmiss
mother
child
mtct
dure
childbirth
intervent
mother
posit
hbsag
20
risk
pass
infect
offspr
time
birth
risk
high
90
mother
posit
hbeag
hbv
transmit
famili
member
household
possibl
contact
nonintact
skin
mucous
membran
secret
saliva
contain
hbv
howev
30
report
hepat
b
adult
associ
identifi
risk
factor
breastfeed
proper
immunoprophylaxi
doe
appear
contribut
mother-to-child-transmiss
mtct
hbv
virus
detect
30
60
day
infect
persist
develop
chronic
hepat
b
incub
period
hepat
b
virus
75
day
averag
vari
30
180
day
virolog
structur
hepat
b
virus
hbv
member
hepadnavirus
famili
virus
particl
virion
consist
outer
lipid
envelop
icosahedr
nucleocapsid
core
compos
protein
virion
30
42
nm
diamet
nucleocapsid
enclos
viral
dna
dna
polymeras
revers
transcriptas
activ
outer
envelop
contain
embed
protein
involv
viral
bind
entri
suscept
cell
virus
one
smallest
envelop
anim
virus
42
nm
virion
capabl
infect
liver
cell
known
hepatocyt
refer
dane
particl
addit
dane
particl
filament
spheric
bodi
lack
core
serum
infect
individu
particl
infecti
compos
lipid
protein
form
surfac
virion
surfac
antigen
hbsag
produc
excess
dure
life
cycl
virus
genom
genom
hbv
circular
dna
unusu
becaus
dna
fulli
double-strand
one
end
length
strand
link
viral
dna
polymeras
genom
3020
3320
nucleotid
long
full-length
strand
1700
2800
nucleotid
long
short
length-strand
negative-sens
non-cod
complementari
viral
mrna
viral
dna
nucleus
soon
infect
cell
partial
double-strand
dna
render
fulli
double-strand
complet
+
sens
strand
remov
protein
molecul
−
sens
strand
short
sequenc
rna
+
sens
strand
non-cod
base
remov
end
−
sens
strand
end
rejoin
four
known
gene
encod
genom
c
x
p
s
core
protein
code
gene
c
hbcag
start
codon
preced
upstream
in-fram
aug
start
codon
pre-cor
protein
produc
hbeag
produc
proteolyt
process
pre-cor
protein
rare
strain
virus
known
hepat
b
virus
precor
mutant
hbeag
present
dna
polymeras
encod
gene
p.
gene
s
gene
code
surfac
antigen
hbsag
hbsag
gene
one
long
open
read
frame
contain
three
frame
start
atg
codon
divid
gene
three
section
pre-s1
pre-s2
s.
becaus
multipl
start
codon
polypeptid
three
differ
size
larg
order
surfac
insid
pre-s1
pre-s2
s
middl
pre-s2
s
small
s
produc
function
protein
code
gene
x
fulli
understood
associ
develop
liver
cancer
stimul
gene
promot
cell
growth
inactiv
growth
regul
molecul
pathogenesi
life
cycl
hepat
b
virus
complex
hepat
b
one
known
pararetrovirus
non-retrovirus
use
revers
transcript
replic
process
virus
gain
entri
cell
bind
ntcp
surfac
endocytos
becaus
virus
multipli
rna
host
enzym
viral
genom
dna
transfer
cell
nucleus
host
protein
chaperon
partial
double-strand
viral
dna
fulli
doubl
strand
viral
polymeras
transform
coval
close
circular
dna
cccdna
cccdna
serv
templat
transcript
four
viral
mrnas
host
rna
polymeras
largest
mrna
longer
viral
genom
use
make
new
copi
genom
make
capsid
core
protein
viral
dna
polymeras
four
viral
transcript
undergo
addit
process
form
progeni
virion
releas
cell
return
nucleus
re-cycl
produc
copi
long
mrna
transport
cytoplasm
virion
p
protein
dna
polymeras
synthes
dna
revers
transcriptas
activ
serotyp
genotyp
virus
divid
four
major
serotyp
adr
adw
ayr
ayw
base
antigen
epitop
present
envelop
protein
eight
major
genotyp
h
genotyp
distinct
geograph
distribut
use
trace
evolut
transmiss
virus
differ
genotyp
affect
diseas
sever
cours
likelihood
complic
respons
treatment
possibl
vaccin
two
genotyp
j
univers
accept
2015
genotyp
differ
8
sequenc
report
1988
six
initi
describ
f
two
type
sinc
describ
g
h
genotyp
divid
subgenotyp
distinct
properti
mechan
hepat
b
virus
primarili
interfer
function
liver
replic
hepatocyt
function
receptor
ntcp
evid
receptor
close
relat
duck
hepat
b
virus
carboxypeptidas
d
virion
bind
host
cell
pres
domain
viral
surfac
antigen
subsequ
intern
endocytosi
hbv-pres-specif
receptor
express
primarili
hepatocyt
howev
viral
dna
protein
detect
extrahepat
site
suggest
cellular
receptor
hbv
exist
extrahepat
cell
dure
hbv
infect
host
immun
respons
caus
hepatocellular
damag
viral
clearanc
innat
immun
respons
doe
play
signific
role
process
adapt
immun
respons
particular
virus-specif
cytotox
t
lymphocyt
ctls
contribut
liver
injuri
associ
hbv
infect
ctls
elimin
hbv
infect
kill
infect
cell
produc
antivir
cytokin
use
purg
hbv
viabl
hepatocyt
liver
damag
initi
mediat
ctls
antigen-nonspecif
inflammatori
cell
worsen
ctl-induc
immunopatholog
platelet
activ
site
infect
facilit
accumul
ctls
liver
diagnosi
test
assay
detect
hepat
b
virus
infect
involv
serum
blood
test
detect
viral
antigen
protein
produc
virus
antibodi
produc
host
interpret
assay
complex
hepat
b
surfac
antigen
hbsag
frequent
use
screen
presenc
infect
detect
viral
antigen
appear
dure
infect
howev
earli
infect
antigen
present
undetect
later
infect
clear
host
infecti
virion
contain
inner
core
particl
enclos
viral
genom
icosahedr
core
particl
180
240
copi
core
protein
altern
known
hepat
b
core
antigen
hbcag
dure
window
host
remain
infect
success
clear
virus
igm
antibodi
specif
hepat
b
core
antigen
anti-hbc
igm
onli
serolog
evid
diseas
therefor
hepat
b
diagnost
panel
contain
hbsag
total
anti-hbc
igm
igg
short
appear
hbsag
anoth
antigen
hepat
b
e
antigen
hbeag
appear
tradit
presenc
hbeag
host
serum
associ
higher
rate
viral
replic
enhanc
infect
howev
variant
hepat
b
virus
produc
e
antigen
rule
doe
alway
hold
true
dure
natur
cours
infect
hbeag
clear
antibodi
e
antigen
anti-hb
aris
immedi
afterward
convers
usual
associ
dramat
declin
viral
replic
host
abl
clear
infect
eventu
hbsag
becom
undetect
follow
igg
antibodi
hepat
b
surfac
antigen
core
antigen
anti-hb
anti
hbc
igg
time
remov
hbsag
appear
anti-hb
window
period
person
negat
hbsag
posit
anti-hb
clear
infect
vaccin
previous
individu
remain
hbsag
posit
six
month
consid
hepat
b
carrier
carrier
virus
chronic
hepat
b
reflect
elev
serum
alanin
aminotransferas
alt
level
inflamm
liver
immun
clearanc
phase
chronic
infect
carrier
seroconvert
hbeag
negat
status
particular
acquir
infect
adult
veri
littl
viral
multipl
henc
littl
risk
long-term
complic
transmit
infect
howev
possibl
individu
enter
immun
escap
hbeag-neg
hepat
pcr
test
develop
detect
measur
hbv
dna
viral
load
clinic
specimen
test
use
assess
person
infect
status
monitor
treatment
individu
high
viral
load
characterist
ground
glass
hepatocyt
biopsi
prevent
vaccin
vaccin
prevent
hepat
b
routin
recommend
babi
sinc
1991
unit
state
dose
general
recommend
day
birth
vaccin
given
three
dose
cours
month
protect
respons
vaccin
defin
anti-hb
antibodi
concentr
10
miu/ml
recipi
serum
vaccin
effect
children
95
percent
vaccin
protect
level
antibodi
drop
90
40
year
age
75
percent
60
year
protect
afford
vaccin
long
antibodi
level
fall
10
miu/ml
newborn
hbsag-posit
mother
hepat
b
vaccin
alon
hepat
b
immunoglobulin
alon
combin
vaccin
plus
hepat
b
immunoglobulin
prevent
hepat
b
occurr
furthermor
combin
vaccin
plus
hepat
b
immunoglobulin
superior
vaccin
alon
combin
prevent
hbv
transmiss
time
birth
86
99
case
tenofovir
given
second
trimest
reduc
risk
mother
child
transmiss
77
combin
hepat
b
immunoglobulin
hepat
b
vaccin
especi
pregnant
women
high
hepat
b
virus
dna
level
howev
suffici
evid
administr
hepat
b
immunoglobulin
alon
dure
pregnanc
reduc
transmiss
rate
newborn
infant
random
control
trial
conduct
assess
effect
hepat
b
vaccin
dure
pregnanc
prevent
infant
infect
risk
exposur
bodi
fluid
blood
vaccin
alreadi
test
verifi
effect
immun
recommend
dose
vaccin
given
suffici
immun
10
22-year
follow-up
studi
case
hepat
b
normal
immun
vaccin
onli
rare
chronic
infect
document
vaccin
particular
recommend
high
risk
group
includ
health
worker
peopl
chronic
renal
failur
men
sex
men
type
hepat
b
vaccin
plasma-deriv
vaccin
pdv
recombin
vaccin
rv
similar
effect
prevent
infect
healthcar
worker
chronic
renal
failur
group
one
differ
notic
health
worker
group
rv
intramuscular
rout
signific
effect
compar
rv
intraderm
rout
administr
assist
reproduct
technolog
sperm
wash
necessari
male
hepat
b
prevent
transmiss
unless
femal
partner
effect
vaccin
femal
hepat
b
risk
transmiss
mother
child
ivf
differ
risk
spontan
concept
high
risk
infect
test
effect
treatment
diseas
group
screen
recommend
includ
vaccin
one
follow
peopl
area
world
hepat
b
occur
2
hiv
intraven
drug
user
men
sex
men
live
someon
hepat
b.
treatment
acut
hepat
b
infect
doe
usual
requir
treatment
adult
clear
infect
spontan
earli
antivir
treatment
requir
fewer
1
peopl
infect
veri
aggress
cours
fulmin
hepat
immunocompromis
hand
treatment
chronic
infect
necessari
reduc
risk
cirrhosi
liver
cancer
chronic
infect
individu
persist
elev
serum
alanin
aminotransferas
marker
liver
damag
hbv
dna
level
candid
therapi
treatment
six
month
year
depend
medic
genotyp
treatment
durat
medic
taken
mouth
howev
variabl
usual
longer
one
year
avail
medic
clear
infect
stop
virus
replic
minim
liver
damag
2018
eight
medic
licens
treatment
hepat
b
infect
unit
state
includ
antivir
medic
lamivudin
adefovir
tenofovir
disoproxil
tenofovir
alafenamid
telbivudin
entecavir
two
immun
modul
interferon
alpha-2a
pegyl
interferon
alpha-2a
2015
world
health
organ
recommend
tenofovir
entecavir
first-lin
agent
current
cirrhosi
need
treatment
use
interferon
requir
inject
daili
thrice
week
supplant
long-act
pegyl
interferon
inject
onli
onc
week
howev
individu
like
respond
becaus
genotyp
infect
virus
person
hered
treatment
reduc
viral
replic
liver
therebi
reduc
viral
load
virus
particl
measur
blood
respons
treatment
differ
genotyp
interferon
treatment
produc
e
antigen
seroconvers
rate
37
genotyp
onli
6
seroconvers
type
d.
genotyp
b
similar
seroconvers
rate
type
type
c
seroconvert
onli
15
case
sustain
e
antigen
loss
treatment
~
45
type
b
onli
25
30
type
c
d.
prognosi
hepat
b
virus
infect
acut
self-limit
chronic
long-stand
person
self-limit
infect
clear
infect
spontan
week
month
children
like
adult
clear
infect
95
peopl
becom
infect
adult
older
children
stage
recoveri
develop
protect
immun
virus
howev
drop
30
younger
children
onli
5
newborn
acquir
infect
mother
birth
clear
infect
popul
40
lifetim
risk
death
cirrhosi
hepatocellular
carcinoma
infect
age
one
six
70
clear
infect
hepat
d
hdv
occur
onli
concomit
hepat
b
infect
becaus
hdv
use
hbv
surfac
antigen
form
capsid
co-infect
hepat
d
increas
risk
liver
cirrhosi
liver
cancer
polyarter
nodosa
common
peopl
hepat
b
infect
cirrhosi
number
differ
test
avail
determin
degre
cirrhosi
present
transient
elastographi
fibroscan
test
choic
expens
aspart
aminotransferas
platelet
ratio
index
use
cost
issu
reactiv
hepat
b
virus
dna
persist
bodi
infect
peopl
diseas
recur
rare
reactiv
seen
follow
alcohol
drug
use
peopl
impair
immun
hbv
goe
cycl
replic
non-repl
approxim
50
overt
carrier
experi
acut
reactiv
male
baselin
alt
200
ul/l
three
time
like
develop
reactiv
peopl
lower
level
reactiv
occur
spontan
peopl
undergo
chemotherapi
higher
risk
immunosuppress
drug
favor
increas
hbv
replic
inhibit
cytotox
t
cell
function
liver
risk
reactiv
vari
depend
serolog
profil
detect
hbsag
blood
greatest
risk
onli
antibodi
core
antigen
risk
presenc
antibodi
surfac
antigen
consid
marker
immun
doe
preclud
reactiv
treatment
prophylact
antivir
drug
prevent
morbid
associ
hbv
diseas
reactiv
epidemiolog
2004
estim
350
million
individu
infect
worldwid
nation
region
preval
rang
10
asia
0.5
unit
state
northern
europ
rout
infect
includ
vertic
transmiss
childbirth
earli
life
horizont
transmiss
bite
lesion
sanitari
habit
adult
horizont
transmiss
sexual
contact
intraven
drug
use
primari
method
transmiss
reflect
preval
chronic
hbv
infect
given
area
low
preval
area
continent
unit
state
western
europ
inject
drug
abus
unprotect
sex
primari
method
factor
import
moder
preval
area
includ
eastern
europ
russia
japan
2
7
popul
chronic
infect
diseas
predomin
spread
children
high-preval
area
china
south
east
asia
transmiss
dure
childbirth
common
area
high
endem
africa
transmiss
dure
childhood
signific
factor
preval
chronic
hbv
infect
area
high
endem
8
10
15
preval
africa/far
east
2010
china
120
million
infect
peopl
follow
india
indonesia
40
million
12
million
respect
accord
world
health
organ
estim
600,000
peopl
die
everi
year
relat
infect
unit
state
19,000
new
case
occur
2011
near
90
1990
histori
hepat
b
virus
infect
human
sinc
bronz
age
evid
obtain
4,500-year-old
human
remain
accord
2018
studi
viral
genom
obtain
shotgun
sequenc
becam
oldest
recov
vertebr
sampl
ancient
hepat
viral
strain
infect
human
becam
extinct
disprov
belief
hepat
b
origin
new
world
spread
europ
16th
centuri
anoth
2018
studi
remain
mummifi
child
basilica
san
domenico
maggior
napl
conclud
child
live
16th
centuri
form
hbv
virus
close
relat
modern
variant
earliest
record
epidem
caus
hepat
b
virus
lurman
1885
outbreak
smallpox
occur
bremen
1883
1,289
shipyard
employe
vaccin
lymph
peopl
sever
week
eight
month
later
191
vaccin
worker
becam
ill
jaundic
diagnos
suffer
serum
hepat
employe
inocul
differ
batch
lymph
remain
healthi
lurman
paper
regard
classic
exampl
epidemiolog
studi
prove
contamin
lymph
sourc
outbreak
later
numer
similar
outbreak
report
follow
introduct
1909
hypoderm
needl
use
import
reus
administ
salvarsan
treatment
syphili
virus
discov
1966
baruch
blumberg
work
nation
institut
health
nih
discov
australia
antigen
later
known
hepat
b
surfac
antigen
hbsag
blood
australian
aborigin
peopl
virus
suspect
sinc
research
publish
frederick
maccallum
1947
david
dane
discov
virus
particl
1970
electron
microscopi
earli
1980s
genom
virus
sequenc
vaccin
test
societi
cultur
world
hepat
day
observ
juli
28
aim
rais
global
awar
hepat
b
hepat
c
encourag
prevent
diagnosi
treatment
led
world
hepat
allianc
sinc
2007
2010
receiv
global
endors
world
health
organ
infecti
caus
cancer
oncovirus
refer
extern
link
hepat
b
curli
